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LETTERS TO THE EDITOR
Problems in the Measurement of Lp(a)
(Millimoles per Liter Versus Milligrams Percent)
I am writing you regarding an article by von Eckardstein et al.
published in JACC, Vol. 37, pp. 434–9, 2001, on “Lipoprotein(a)
Further Increases the Risk of Coronary Events in Men With High
Global Cardiovascular Risk.” The authors are to be complimented
for conducting a large study using their PROCAM population
where they were able to obtain a long follow-up and also for
making the measurements in fresh serum, which reduces many of
the errors previously seen in Lp(a) assays.
However, despite these precautions, the study still has a major
problem. In their article, Lp(a) is measured in the units of g/l.
These units have little meaning in terms of the quantity of Lp(a)
present in the plasma, as the (a) of Lp(a) is noted to have a
molecular weight that can vary between 250,000 and 750,000
daltons. This variation is determined by a total of over 30
genetically determined alleles. Thus, there are 30  30, or 900
possible variations in the molecular weight of this protein in the
patient’s plasma, and each patient will have the possibility of any
two of these 900 combinations. With this marked variation in
molecular weight, it is impossible to calculate the true concentra-
tions of this protein in terms of g/l. To do so, one must assume an
average molecular weight for the compound. This is very difficult
because the distribution of variation in the size of the compound is
not random, but is well-known to vary widely in different racial
populations. The only solution to this problem is to use an assay
that measures Lp(a) in units of millimoles per liter. This can be
done either by using antibodies that react only with the nonre-
peating portions of the (a) sequence (i.e., those regions not
included in kringle IV) or by capturing the particles with antibod-
ies to (a) and detecting with antibodies to apo B. Methods for
using these techniques have been published previously.
It is unfortunate that in this large study these methods were not
utilized. As a result, the data are very difficult to interpret because they
represent variations of two factors: 1) variation in the size of (a), which
may well be related to disease and which would be reflected indirectly
in the concentrations measured by methods using a g/l unit; or 2)
variation in the concentration of particles of Lp (a) in the plasma,
which may be determined by many other clinical factors.
It is unfortunate that these methods have become utilized
extensively in the literature. They are leading to a great deal of
confusion and actually represent biochemical artifacts. Until we get
a reasonable standardization of Lp(a) assays, it is very difficult to
interpret any studies such as those reported in the article by Von
Eckardstein et al. I would make a plea for people working in this
area to get together to develop a true measure of the Lp(a) that is
not affected by variations in the molecular size of (a). When such
is done, we can then determine which clinical factors are related to
variations in the concentration of Lp(a) particles (the number of
particles/ml) versus those that are related to genetically determined
differences in the size of (a).
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REPLY
We are grateful to Dr. Kottke for raising an important point. Lack
of standardization has been a big problem in comparing Lp(a) data
from different studies and in defining the threshold value above
which cardiovascular risk is increased. A working group supported
by the National Institutes of Health/National Heart, Lung and
Blood Institute (NIH/NHLBI) evaluated 22 Lp(a) assays using
reference material developed by the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) and a
reference assay designed as proposed by Dr. Kottke (1). Using a
test panel consisting of 30 samples, the coefficients of variation
among systems varied from 6% to 31%, with some assays biased
toward higher and some toward lower Lp(a) values. In agreement
with the point raised by Dr. Kottke, a major source of this bias was
heterogeneity in the size of apo(a). Overall, however, results of the
various Lp(a) assays correlated well. Nevertheless, this bias is an
important factor contributing to discrepancies in the suggested risk
threshold values for Lp(a), which vary from 0.2 g/l to 0.3 g/l. To
put it another way, at a given Lp(a) risk threshold, some assays will
overestimate and some will underestimate the cardiovascular risk,
especially in persons whose Lp(a) concentration is close to the
suggested cutoff.
Thus, we agree with Dr. Kottke that Lp(a) measurements
should be performed with standardized assays to allow comparison
of data and definition of a universally acceptable risk threshold
value. Calibration of the various assays using common reference
material is not sufficient for this purpose, as only 2 of the 22 tests
investigated by the NIH/NHLBI/IFCC working group showed
good agreement with the reference assay despite identical calibra-
tion. Manufacturers should optimize their Lp(a) assays using
well-defined antibodies and evaluate their results obtained by
comparison with a reference test. One alternative to standardized
apo(a) immunoassays might be the measurement of the cholesterol
content of Lp(a), a variable identified as a cardiovascular risk factor
in the Framingham Heart Study (2).
Standardized tests were not available when we measured Lp(a)
in PROCAM more than 15 years ago (3). Despite this, we
consider our data to be clinically useful. Even though the levels
given are in arbitrary units rather than mass concentrations, our
measurements clearly show an elevated level of Lp(a) to be
associated with increased cardiovascular risk, particularly when it
coincides with other risk factors. As outlined above, the risk
threshold value remains to be established and may not be the 0.2
g/l suggested by us, even though this value is close to the 80th
percentile in the population, a cutoff suggested by the NIH/
NHLBI/IFCC working group.
Finally, Lp(a) does not show a stringent dose-response relation-
ship with cardiovascular events (see Fig. 1 of our article, ref. 3). For
this reason, the best way to define a threshold value for cardiovas-
cular risk would be to apply a receiver operating characteristics
curve analysis to results obtained using a standardized Lp(a) assay
in a prospective study.
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Atrial Fibrillation and
Sinus Node Dysfunction
We have read with great interest the article by Lombardi et al. (1),
which used analysis of heart rate variability (HRV) to predict
recurrence of atrial fibrillation (AF) after electrical cardioversion.
Although analysis of HRV in this setting is technically demanding
(owing to ectopy) the investigators showed that patients with an
early recurrence of AF (within two weeks after cardioversion) are
characterized by a high low-frequency/high-frequency ratio com-
pared to patients who maintain sinus rhythm. Based on the
implicit assumption that HRV reflects autonomic modulation of
the sinus node, Lombardi et al. (1) concluded that sympathetic
modulation is increased in these patients. However, it is question-
able whether this assumption is valid in the present setting. For the
sinus node to reflect autonomic modulation it is required that sinus
node function as such is normal. In other words, in case of intrinsic
dysfunction, the sinus node is not an adequate “thermometer,” and
HRV should not be used to assess autonomic modulation. In
patients with persistent AF there is reason to doubt whether
intrinsic sinus node function is normal.
First, AF is often associated with sick sinus syndrome (2). In
fact, histopathological studies demonstrated that persistent AF is
associated with significant damage to the sinus node, the perinodal
tissue and the sinus node artery (3). Second, and possibly even
more important, AF per se causes sinus node dysfunction.
In an experimental pacing-model in dogs, Elvan et al. (4)
examined the effect of AF on sinus node function. Intrinsic
function was assessed after pharmacological autonomic blockade
using propranolol and atropine. No effect was apparent after 1 h of
AF, but prolonged AF (two to six weeks) caused a significant
increase in intrinsic-corrected sinus node recovery time and a
decrease in intrinsic heart rate. Within one week after cessation of
AF these measures of sinus node function gradually returned to
normal. Comparable data have recently been reported in humans
(5). It thus appears that electrical remodeling secondary to AF is
not confined to the atrial myocardium but also involves the sinus
node.
The clinical data provided by Lombardi et al. (1) on their
patients do not indicate intrinsic sinus node dysfunction. Con-
versely, intrinsic sinus node dysfunction is hard to rule out.
Therefore, we believe that the conclusion by Lombardi et al. (1),
namely that patients with early recurrence of AF show signs of
increased sympathetic modulation, should be toned down.
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The letter of van den Berg and van Gelder questions whether
electrical remodeling of the sinus node might affect interpretation
of heart rate variability parameters measured after successful
cardioversion of chronic atrial fibrillation (AF).
The issue is of relevance and must be considered within a recent
number of observations indicating the complexity of the electrical
remodeling process in relation not only to AF duration but also to
different atrial sites and sinus node involvement.
We have recently reported (1) that after successful electrical
cardioversion of chronic AF in patients pre-treated with amioda-
rone, the presence of a distinct short-term heart rate variability
pattern characterized by an low frequency/high frequency (LF/
HF) ratio 2 is associated with an 8-fold increased risk of early
recurrence. In contrast, patients with a LF/HF ratio2 were more
likely to maintain sinus rhythm.
We therefore concluded that signs of increased sympathetic and
reduced vagal modulation of the sinus node were characteristic of
patients with an early AF recurrence, and we hypothesized that
abnormal autonomic control could play a pro-arrhythmic role by
influencing electrical remodeling.
We are aware of the data suggesting that, in patients with
chronic atrial flutter, signs of electrical remodeling of sinus node
can be detected after cardioversion (2). However, in our opinion, it
is difficult to evaluate the clinical significance of these findings
obtained during pharmacological autonomic blockade and their
possible effect on spectral parameters of heart rate variability. Two
factors seem to deny this possibility. First, we observed an increase
rather than a decrease in low frequency oscillations in patients with
early recurrence of atrial fibrillation. This pattern, together with
reduction of the high-frequency oscillation, is unlikely to reflect a
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